Necessity and safety of conversion from mycophenolate mofetil to AzA thioprine after renal transplantation

National Medical Journal of China

Volumn 85, Issue 10, 2005, Pages 657-660

  Lu, Jin Shan ^a   Xiao, Xu Ren ^b   Ao, Jian Hua ^b   Gao, Jiang Ping ^b   Dong, Jun ^b   Hong, Bao Fa ^b   Li, Yan Tang ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NONE

Author keywords

Clinical studies; Graft rejection; Immunosuppressive agents; Kidney transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; FOLLOW UP; GRAFT SURVIVAL; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; INCIDENCE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RISK ASSESSMENT; SIDE EFFECT;

ADOLESCENT; ADULT; AZATHIOPRINE; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; SAFETY;

EID: 15844384994     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Mark A. Schnitzler, Karen E. Craig, Karen E. Hardinger, et al. Mycophenolate mofetil is associated with less death with function than Azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant,2003,18:1197-1200.
2. Rudolf P. Wuthrich, Snjezana Cicvara, Patrice M, et al. Randomized trial of conversion from mycophenolate mofetil to Azathioprine 6 months after renal allograft transplantation. Nephrol Dial Transplant, 2000,15:1228-1231.
3. Keven K, Sahin M, Kutlay S, et al. Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and Azathioprine. Transpl Infect Dis, 2003,5:181-186.
4. Pallardo Mateu LM, Sancho Calabuig A, Capdevila Plaza L, et al. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant, 2004,19:38-42.
5. Coll E, Crespo M, Sole M, et al. Lessons from cyclosporine monotherapy in renal transplantation: the impact of acute rejection on long-term allograft outcome. Transplant Proc, 2004,36:114-116.
6. Sundaram Hariharan, Christopher P. Johnson, Barbara A. Bresnahan, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med, 2000,342:605-612.
7. Nowacka-Cieciura E, Kaminska B, Cieciura T, et al. Randomised open clinical trial of conversion from mycophenolate mofetil to azathioprine in cadaveric renal transplantation. Transpl Int, 2000, 13:S68-72.
8. Taylor DO, Sharma RC, Kfoury AG, et al. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Clin Transplant,1999,13:296-299.
9. Joseph JT, Kingsmore DB, Junor BJ, et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant, 2001,15:221-227.
10. Gonzalez Molina M, Seron D, Garcia del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the spanish cooperative study group of chronic allograft nephropathy. Transplantation, 2004,77:215-220.